Stocks were rising on Wednesday following the Federal Reserve’s decision to hold interest rates steady. The central bank ...
Zacks Investment Research on MSN15h
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsThe most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health ...
GlobalData on MSN9d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback